DESTINY-Breast03 Phase 3 Study Results

Time to First Occurrence of Fatigue and Alopecia 10 Daiichi-Sankyo DESTINY-Breast03 Cumulative Probability + Censor Fatigue 1.0 - T-DXd 0.9- -T-DM1 P = 0.2376 0.8- 0.7- 0.6- 0.5- 1.0. + Censor Alopecia T-DXd 0.4- 0.3- 0.2- 0.1- பட Cumulative Probability 0.9 T-DM1 0.8. P<0.0001 0.7- 0.6- 0.5- 0.4- 0.3- 0.2- 0.1- LIL 0.0 0.0- 0 g- 90 180 270 360 450 540 630 720 810 900 990 1080 0 90 180 270 360 450 540 630 720 810 900 990 1080 Days Days T-DXd 257 T-DM1 261 201 175 171 148 125 105 74 41 19 9 1 0 117 78 49 37 27 13 1 0 T-DXd 257 T-DM1 261 168 140 123 105 86 59 32 17 8 2 1 0 206 146 100 67 50 38 19 7 3 0 • The cumulative incidence and trend of fatigue over time was similar between T-DXd and T-DM1 Risk of first event of alopecia was higher with T-DXd in earlier cycles T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event. Time to first occurrence of the TEAE was defined as the date of the first occurrence of the TEAE minus the date of first study drug plus 1. Patients that did not experience the TEAE were censored at min (treatment end date + 47 days, new treatment start date, death date, date last known alive) minus first study drug date plus 1. P value was from the unstratified log rank test and was for descriptive purposes only. ASCO 2022 #1000 Oral 31

View entire presentation